{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,18]],"date-time":"2026-01-18T13:15:32Z","timestamp":1768742132191,"version":"3.49.0"},"reference-count":34,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2015,5,1]],"date-time":"2015-05-01T00:00:00Z","timestamp":1430438400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100008121","name":"Israel Ministry of Defense","doi-asserted-by":"crossref","award":["039-4489"],"award-info":[{"award-number":["039-4489"]}],"id":[{"id":"10.13039\/501100008121","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100008121","name":"Israel Ministry of Defense","doi-asserted-by":"crossref","award":["039-4576"],"award-info":[{"award-number":["039-4576"]}],"id":[{"id":"10.13039\/501100008121","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["epilepsybehavior.com","clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Epilepsy &amp; Behavior"],"published-print":{"date-parts":[[2015,5]]},"DOI":"10.1016\/j.yebeh.2015.02.040","type":"journal-article","created":{"date-parts":[[2015,4,11]],"date-time":"2015-04-11T02:57:00Z","timestamp":1428721020000},"page":"72-78","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"special_numbering":"C","title":["Pharmacodynamic and pharmacokinetic analysis of CNS-active constitutional isomers of valnoctamide and sec-butylpropylacetamide \u2014 Amide derivatives of valproic acid"],"prefix":"10.1016","volume":"46","author":[{"given":"Hafiz","family":"Mawasi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tawfeeq","family":"Shekh-Ahmad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard H.","family":"Finnell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bogdan J.","family":"Wlodarczyk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Meir","family":"Bialer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.yebeh.2015.02.040_bb0005","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1016\/S0009-9236(97)90194-6","article-title":"Stereoselective pharmacokinetic analysis of valnoctamide in healthy subjects and in patients with epilepsy","volume":"61","author":"Barel","year":"1997","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.yebeh.2015.02.040_bb0010","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.nurt.2006.11.007","article-title":"Valproic acid \u2014 second generation","volume":"4","author":"Bialer","year":"2007","journal-title":"Neurotherapeutics"},{"key":"10.1016\/j.yebeh.2015.02.040_bb0015","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1016\/j.addr.2011.11.006","article-title":"Chemical properties of antiepileptic drugs (AEDs)","volume":"64","author":"Bialer","year":"2012","journal-title":"Adv Drug Deliv Rev"},{"key":"10.1016\/j.yebeh.2015.02.040_bb0020","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1007\/BF00315032","article-title":"Pharmacokinetics of a valpromide isomer, valnoctamide, in healthy subjects","volume":"38","author":"Bialer","year":"1990","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.yebeh.2015.02.040_bb0025","doi-asserted-by":"crossref","first-page":"114","DOI":"10.2165\/00003088-199120020-00003","article-title":"Clinical pharmacology of valpromide","volume":"20","author":"Bialer","year":"1991","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.yebeh.2015.02.040_bb0030","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1038\/nrd2997","article-title":"Key factors in the discovery and development of new antiepileptic drugs (AEDs)","volume":"9","author":"Bialer","year":"2010","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.yebeh.2015.02.040_bb0035","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1111\/j.1528-1167.2011.03338.x","article-title":"A new derivative of valproic acid amide possesses a broad-spectrum antiseizure profile and unique activity against status epilepticus and organophosphate neuronal damage","volume":"53","author":"White","year":"2012","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2015.02.040_bb0040","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.neuroscience.2012.11.005","article-title":"Electrographic analysis of the effect of sec-butyl-propylacetamide on pharmacoresistant status epilepticus","volume":"231","author":"Pouliot","year":"2013","journal-title":"Neuroscience"},{"key":"10.1016\/j.yebeh.2015.02.040_bb0045","doi-asserted-by":"crossref","first-page":"6467","DOI":"10.1021\/jm4007565","article-title":"Stereoselective pharmacodynamic and pharmacokinetic analysis of sec-propyl-butylacetamide (SPD), a new CNS-active derivative of valproic acid with unique activity against status epilepticus","volume":"56","author":"Hen","year":"2013","journal-title":"J Med Chem"},{"issue":"12","key":"10.1016\/j.yebeh.2015.02.040_bb0050","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1111\/j.1399-5618.2010.00828.x","article-title":"Valnoctamide as valproate substitute with low teratogenic potential in mania: double blind controlled clinical trial","author":"Bersudsky","year":"2010","journal-title":"Bipolar Disord"},{"issue":"103","key":"10.1016\/j.yebeh.2015.02.040_bb0055","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.eplepsyres.2012.10.001","article-title":"Progress report on new antiepileptic drugs: a summary of the eleventh Eilat Conference (EILAT XI)","author":"Bialer","year":"2013","journal-title":"Epilepsy Res"},{"issue":"111","key":"10.1016\/j.yebeh.2015.02.040_bb0060","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.eplepsyres.2015.01.001","article-title":"Progress report on new antiepileptic drugs: a summary of the twelfth Eilat Conference (EILAT XII)","author":"Bialer","year":"2015","journal-title":"Epilepsy Res"},{"key":"10.1016\/j.yebeh.2015.02.040_bb0065","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1111\/epi.12290","article-title":"Valnoctamide and sec-propyl-butylacetamide (SPD) for acute seizures and status epilepticus","volume":"54","author":"Shekh-Ahmad","year":"2013","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2015.02.040_bb0070","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1111\/epi.12480","article-title":"Stereoselective anticonvulsant and pharmacokinetic analysis of valnoctamide, a new CNS-active derivative of valproic acid with low teratogenic potential","volume":"55","author":"Shekh-Ahmad","year":"2014","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2015.02.040_bb0075","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1016\/j.neuropharm.2010.03.004","article-title":"Evaluation of the antiallodynic, teratogenic and pharmacokinetic profile of stereoisomers of valnoctamide, an amide derivative of a chiral isomer of valproic acid","volume":"52","author":"Kaufmann","year":"2010","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.yebeh.2015.02.040_bb0080","series-title":"Handbook of experimental pharmacology 124 (drug toxicity in embryonic development II)","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1007\/978-3-642-60447-8_3","article-title":"Anticonvulsant drugs: mechanisms and pathogenesis of teratogenicity","author":"Finnell","year":"1997"},{"key":"10.1016\/j.yebeh.2015.02.040_bb0085","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1002\/tera.1420380403","article-title":"Common hierarchies of susceptibility to the induction of neural tube defects in mouse embryos by valproic acid and its 4-propyl-4-pentenoic acid metabolite","volume":"38","author":"Finnell","year":"1988","journal-title":"Teratology"},{"key":"10.1016\/j.yebeh.2015.02.040_bb0090","doi-asserted-by":"crossref","first-page":"7236","DOI":"10.1021\/jm901229s","article-title":"Synthesis and evaluation of the antiallodynic of novel amide and urea derivatives of valproic acid analogues","volume":"52","author":"Kaufmann","year":"2009","journal-title":"J Med Chem"},{"key":"10.1016\/j.yebeh.2015.02.040_bb0095","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1055\/s-0038-1636052","article-title":"Statistical logic in the monitoring of reactions to therapeutic drugs","volume":"10","author":"Finney","year":"1971","journal-title":"Methods Inf Med"},{"key":"10.1016\/j.yebeh.2015.02.040_bb0100","first-page":"560","article-title":"The disposition of valpromide, valproic acid and valnoctamide in brain, liver, plasma and urine of rats","volume":"24","author":"Blotnik","year":"1996","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.yebeh.2015.02.040_bb0105","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1016\/j.neuropharm.2006.06.006","article-title":"Preclinical evaluation of 2,2,3,3-tetramethylcyclopropanecarbonylurea, a novel second generation to valproic acid, antiepileptic drug","volume":"51","author":"Sobol","year":"2006","journal-title":"Neuropharmacology"},{"issue":"52","key":"10.1016\/j.yebeh.2015.02.040_bb0110","doi-asserted-by":"crossref","first-page":"2233","DOI":"10.1021\/jm900017f","article-title":"\u03b1-Fluoro-2,2,3,3-teteramethylcylcopropanecarboaxamide a novel potent anticonvulsant derivative of a cyclic analogue of valproic acid","author":"Pessah","year":"2009","journal-title":"J Med Chem"},{"key":"10.1016\/j.yebeh.2015.02.040_bb0115","doi-asserted-by":"crossref","first-page":"e94","DOI":"10.1111\/epi.12702","article-title":"Valnoctamide enhances phasic inhibition: a potential target mechanism for the treatment of benzodiazepine-refectory status epilepticus","volume":"55","author":"Spampanato","year":"2014","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2015.02.040_bb0120","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1023\/A:1015934321764","article-title":"Structure\u2013pharmacokinetic relationship in a series of valpromide isomers with antiepileptic activity","volume":"6","author":"Haj-Yehia","year":"1989","journal-title":"Pharm Res"},{"key":"10.1016\/j.yebeh.2015.02.040_bb0125","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1002\/jps.2600790814","article-title":"Structure pharmacokinetic relation in a series of short fatty acid amides that posses anticonvulsant activity","volume":"79","author":"Haj-Yehia","year":"1990","journal-title":"J Pharm Sci"},{"key":"10.1016\/j.yebeh.2015.02.040_bb0130","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1023\/A:1018960722284","article-title":"Strereoselective pharmacokinetics and pharmacodynamics of propylisopropyl acetamide \u2014 a CNS-active chiral amide derivative of valproic acid","volume":"16","author":"Spiegelman","year":"1999","journal-title":"Pharm Res"},{"key":"10.1016\/j.yebeh.2015.02.040_bb0135","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1056\/NEJMoa0803531","article-title":"Cognitive function at 3years of age after fetal exposure to antiepileptic drugs","volume":"360","author":"Meador","year":"2009","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1016\/j.yebeh.2015.02.040_bb0140","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1016\/S1474-4422(11)70107-7","article-title":"Dose-dependent risk of malformations with antiepileptic drugs: an analysis of data from the EURAP epilepsy and pregnancy registry","author":"Tomson","year":"2011","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.yebeh.2015.02.040_bb0145","author":"European Medicines Agency (EMA)"},{"key":"10.1016\/j.yebeh.2015.02.040_bb0150","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1124\/jpet.108.143420","article-title":"Challenged in the search for drugs to treat central nerve system disorders","volume":"329","author":"Enna","year":"2009","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.yebeh.2015.02.040_bb0155","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1038\/nrd3480","article-title":"How were new medicines discovered?","volume":"10","author":"Swinney","year":"2011","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.yebeh.2015.02.040_bb0160","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/j.eplepsyres.2006.02.004","article-title":"Diverse mechanisms of antiepileptic drugs in development","volume":"69","author":"Rogawski","year":"2006","journal-title":"Epilepsy Res"},{"key":"10.1016\/j.yebeh.2015.02.040_bb0165","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.nurt.2006.11.009","article-title":"Discovery of antiepileptic drugs","volume":"4","author":"Smith","year":"2007","journal-title":"Neurotherapeutics"},{"key":"10.1016\/j.yebeh.2015.02.040_bb0170","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1016\/j.yebeh.2004.08.021","article-title":"Correlation analysis between anticonvulsant ED50 values of antiepileptic drugs in mice and rats and their therapeutic doses and plasma levels","volume":"5","author":"Bialer","year":"2004","journal-title":"Epilepsy Behav"}],"container-title":["Epilepsy &amp; Behavior"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525505015001006?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525505015001006?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,5,4]],"date-time":"2022-05-04T18:23:52Z","timestamp":1651688632000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525505015001006"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,5]]},"references-count":34,"alternative-id":["S1525505015001006"],"URL":"https:\/\/doi.org\/10.1016\/j.yebeh.2015.02.040","relation":{},"ISSN":["1525-5050"],"issn-type":[{"value":"1525-5050","type":"print"}],"subject":[],"published":{"date-parts":[[2015,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pharmacodynamic and pharmacokinetic analysis of CNS-active constitutional isomers of valnoctamide and sec-butylpropylacetamide \u2014 Amide derivatives of valproic acid","name":"articletitle","label":"Article Title"},{"value":"Epilepsy & Behavior","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.yebeh.2015.02.040","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}